Summary

Candesartan may have a place in the treatment of retinopathy in patients with type 1 or 2 diabetes, according to findings from the Diabetic Retinopathy Candesartan Trials (DIRECT) study program. The DIRECT-Protect 1 and 2 trials are the first to show the potential benefits of angiotensin-II receptor blockers in patients with baseline diabetic retinopathy.